Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2019 from OUS - Addiction Treatment Research Units

10 publications found

Hauger LE, Sagoe D, Vaskinn A, Arnevik EA, Leknes S, Jørstad ML, Bjørnebekk A (2019)
Anabolic androgenic steroid dependence is associated with impaired emotion recognition
Psychopharmacology (Berl) (in press)
DOI 10.1007/s00213-019-05239-7, PubMed 30941469

Hauger LE, Westlye LT, Fjell AM, Walhovd KB, Bjørnebekk A (2019)
Structural brain characteristics of anabolic-androgenic steroid dependence in men
Addiction (in press)
DOI 10.1111/add.14629, PubMed 30955206

Havnes IA, Jørstad ML, Wisløff C (2019)
Anabolic-androgenic steroid users receiving health-related information; health problems, motivations to quit and treatment desires
Subst Abuse Treat Prev Policy, 14 (1), 20
DOI 10.1186/s13011-019-0206-5, PubMed 31096999

Helverschou SB, Brunvold AR, Arnevik EA (2019)
Treating Patients With Co-occurring Autism Spectrum Disorder and Substance Use Disorder: A Clinical Explorative Study
Subst Abuse, 13, 1178221819843291
DOI 10.1177/1178221819843291, PubMed 31024216

Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L (2019)
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study
Am J Addict, 28 (2), 77-85
DOI 10.1111/ajad.12859, PubMed 30701613

Muller AE, Bukten A (2019)
Measuring the quality of life of incarcerated individuals
Int J Prison Health, 15 (1), 1-13
DOI 10.1108/IJPH-02-2018-0005, PubMed 30827162

Mørland J, Waal H (2019)
'The entire pharmaceutical compendium' in the treatment of substance use disorders
Tidsskr Nor Laegeforen, 139 (3)
DOI 10.4045/tidsskr.18.0678, PubMed 30754952

Sømhovd M, Hagen E, Bergly T, Arnevik EA (2019)
The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment
Heliyon, 5 (3), e01282
DOI 10.1016/j.heliyon.2019.e01282, PubMed 31025003

Waal H, Mørland JG (2019)
H. Waal og J. Mørland svarer
Tidsskr Nor Laegeforen, 139 (6)
DOI 10.4045/tidsskr.19.0190, PubMed 30917637

Waal H, Mørland JG (2019)
H. Waal og J. Mørland svarer
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.19.0296, PubMed 31062560

 
Page visits: 144556